“djuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

Our study highlights a concerning 3-fold increase in obesity-related cancer deaths since 1999,” said study author Faizan Ahmed, MD.